C 
China Traditional Chinese Medicine Holdings Co 570.HK · HKD
Health Care · HKEX · 🇭🇰 Hong Kong
1.19
-0.83%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥16.51bn
FY2015FY2024
Net income
CN¥54.1m
FY2015FY2024
Free cash flow
CN¥2.07bn
FY2015FY2024
Shareholders' equity
CN¥21.20bn
FY2015FY2024
Income statement
Fiscal years
| FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥16.51bn | CN¥18.12bn | CN¥14.30bn | CN¥19.05bn | CN¥14.81bn | CN¥14.32bn | CN¥11.26bn | CN¥8.34bn | CN¥6.53bn | CN¥3.71bn |
| Gross profit | CN¥7.86bn | CN¥9.27bn | CN¥7.20bn | CN¥11.83bn | CN¥9.13bn | CN¥8.58bn | CN¥6.19bn | CN¥4.65bn | CN¥3.79bn | CN¥2.20bn |
| Research and development | CN¥596.0m | CN¥685.6m | CN¥611.8m | CN¥694.4m | CN¥550.5m | CN¥464.0m | CN¥346.5m | CN¥202.2m | CN¥186.8m | CN¥112.3m |
| Operating income | CN¥751.8m | CN¥1.35bn | CN¥1.17bn | CN¥2.71bn | CN¥2.51bn | CN¥2.43bn | CN¥2.10bn | CN¥1.76bn | CN¥1.20bn | CN¥648.1m |
| Net income | CN¥54.1m | CN¥1.29bn | CN¥764.5m | CN¥1.93bn | CN¥1.66bn | CN¥1.59bn | CN¥1.44bn | CN¥1.17bn | CN¥966.9m | CN¥625.6m |
| Diluted earnings per share | 0.01 | 0.26 | 0.15 | 0.38 | 0.33 | 0.32 | 0.30 | 0.26 | 0.22 | 0.16 |
Balance sheet
At each fiscal year end
| FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥35.06bn | CN¥37.07bn | CN¥35.64bn | CN¥36.39bn | CN¥33.09bn | CN¥32.47bn | CN¥30.29bn | CN¥24.89bn | CN¥21.04bn | CN¥19.21bn |
| Cash and short-term investments | CN¥5.34bn | CN¥3.90bn | CN¥3.67bn | CN¥4.14bn | CN¥5.03bn | CN¥6.80bn | CN¥6.42bn | CN¥4.79bn | CN¥2.40bn | CN¥2.20bn |
| Total liabilities | CN¥13.86bn | CN¥15.91bn | CN¥15.47bn | CN¥16.67bn | CN¥15.02bn | CN¥15.85bn | CN¥14.74bn | CN¥12.45bn | CN¥9.45bn | CN¥8.08bn |
| Debt | CN¥4.02bn | CN¥5.16bn | CN¥5.04bn | CN¥5.06bn | CN¥5.22bn | CN¥5.71bn | CN¥6.13bn | CN¥5.15bn | CN¥3.91bn | CN¥2.45bn |
| Shareholders' equity | CN¥21.20bn | CN¥21.16bn | CN¥20.17bn | CN¥19.72bn | CN¥18.06bn | CN¥16.62bn | CN¥15.55bn | CN¥12.44bn | CN¥11.59bn | CN¥11.13bn |
| Shares outstanding | 5,036m | 5,036m | 5,036m | 5,036m | 5,036m | 5,036m | 4,822m | 4,432m | 4,450m | 3,687m |
Cash flow
Fiscal years
| FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥2.58bn | CN¥1.17bn | CN¥1.09bn | CN¥796.0m | CN¥228.5m | CN¥1.59bn | CN¥1.19bn | CN¥1.24bn | CN¥1.46bn | CN¥518.7m |
| Capital spending | −CN¥512.1m | −CN¥488.6m | −CN¥527.3m | −CN¥877.2m | −CN¥1.25bn | −CN¥1.17bn | −CN¥966.2m | −CN¥602.9m | −CN¥202.9m | −CN¥225.8m |
| Free cash flow | CN¥2.07bn | CN¥680.2m | CN¥565.1m | −CN¥81.2m | −CN¥1.02bn | CN¥411.8m | CN¥224.3m | CN¥632.7m | CN¥1.26bn | CN¥292.9m |
| Dividends paid | — | −CN¥240.0m | −CN¥314.4m | −CN¥275.8m | −CN¥216.3m | −CN¥502.5m | −CN¥479.7m | −CN¥316.1m | −CN¥245.1m | — |
Latest quarters
By quarter end
| Jun 2025 | Dec 2024 | Jun 2024 | Dec 2023 | Jun 2023 | Dec 2022 | Jun 2022 | Dec 2021 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥7.46bn | CN¥8.12bn | CN¥8.39bn | CN¥8.82bn | CN¥9.30bn | CN¥8.39bn | CN¥5.91bn | CN¥10.90bn |
| Gross profit | CN¥3.63bn | CN¥3.80bn | CN¥4.06bn | CN¥4.52bn | CN¥4.76bn | CN¥4.25bn | CN¥2.95bn | CN¥6.83bn |
| Operating income | CN¥191.6m | CN¥382.7m | CN¥369.1m | CN¥572.3m | CN¥783.2m | CN¥633.4m | CN¥540.2m | CN¥1.41bn |
| Net income | −CN¥107.9m | −CN¥156.9m | CN¥211.0m | CN¥706.5m | CN¥578.7m | CN¥350.9m | CN¥413.6m | CN¥1.00bn |
| Diluted earnings per share | -0.02 | -0.03 | 0.04 | 0.14 | 0.11 | 0.07 | 0.08 | 0.20 |
| Total assets | CN¥34.53bn | CN¥35.06bn | CN¥37.55bn | CN¥37.07bn | CN¥38.42bn | CN¥35.64bn | CN¥37.92bn | CN¥36.39bn |
| Cash and short-term investments | CN¥5.17bn | CN¥5.34bn | CN¥4.54bn | CN¥3.90bn | CN¥4.80bn | CN¥3.67bn | CN¥6.00bn | CN¥4.14bn |
| Debt | CN¥297.3m | CN¥1.89bn | CN¥2.01bn | CN¥2.19bn | CN¥2.22bn | CN¥528.9m | CN¥619.8m | CN¥2.89bn |
| Shareholders' equity | CN¥20.70bn | CN¥21.20bn | CN¥21.37bn | CN¥21.16bn | CN¥20.51bn | CN¥20.17bn | CN¥19.81bn | CN¥19.72bn |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | -4.7% | 2.9% | 20.1% |
| Operating income | -34.8% | -20.9% | 3.1% |
| Net income | -69.6% | -49.1% | -18.4% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 49.5% | 53.2% | 55.5% | 55.8% |
| Operating margin | 6.1% | 8.8% | 11.3% | 13.3% |
| Net margin | 3.9% | 5.9% | 7.5% | 9.2% |
Valuation history
At each fiscal year end
| FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 189.2 | 8.8 | 13.3 | 7.7 | 6.6 | 6.8 | 8.7 | 9.0 | 9.4 | 17.6 |
| Price to sales | 0.6 | 0.6 | 0.7 | 0.8 | 0.8 | 0.8 | 1.1 | 1.3 | 1.4 | 3.0 |
Dividends and splits
Per share, in the currency the company pays
Paid for 1 years. Last went ex-dividend on 3 Jul 2025.
| FY2025 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 0.007 | 0.052 | 0.074 | 0.067 | 0.048 | 0.112 | 0.11 | 0.083 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.